1. ALLA AKTIER
  2. NYHETER
  3. IDL DIAGNOSTICS

IDL Diagnostics

Nyheter IDL Diagnostics Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

AroCell publishes the Annual Report for 2022

MARKN.

AroCell hereby announces that the annual report for 2022 has been published and is available on the company’s website: www.arocell.com.
 
The annual report is available at the following link: www.arocell.com/investors/financial-reports/
 
The report is available in Swedish only.
 

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Attachments

AroCell Årsredovisning 2022

Datum 2023-04-12, kl 08:00
Källa MFN
Bifogade filer
AroCell Årsredovisning 2022